SyntheX

Synthe X

Biotechnology, 409 St, San Francisco, California, Illinois, 94158, United States, 11-50 Employees

synthexlabs.com

  • twitter
  • LinkedIn

phone no Phone Number: 17*********

Who is SYNTHEX

SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-v...

Read More

map
  • 409 Illinois St, San Francisco, California, 94158, United States Headquarters: 409 Illinois St, San Francisco, California, 94158, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from SYNTHEX

SyntheX Org Chart and Mapping

Employees

Similar Companies to SyntheX

Aralez Bio

  • 11-50 11-50
  • Under 1 Million $ Under 1 Million

Mammoth Biosciences

  • 51-200 51-200
  • 1 Million to 5 Million $ 1 Million to 5 Million

Pivot Bio

  • 201-500 201-500
  • 250 Million to 500 Million $ 250 Million to 500 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SyntheX

Answer: SyntheX's headquarters are located at 409 St, San Francisco, California, Illinois, 94158, United States

Answer: SyntheX's phone number is 17*********

Answer: SyntheX's official website is https://synthexlabs.com

Answer: SyntheX's revenue is $1 Million to $5 Million

Answer: SyntheX's SIC: 8731

Answer: SyntheX has 11-50 employees

Answer: SyntheX is in Biotechnology

Answer: SyntheX top competitors include: Aralez Bio , Mammoth Biosciences , Pivot Bio

Answer: SyntheX contact info: Phone number: 17********* Website: https://synthexlabs.com

Answer: SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner. Our lead programs focus on oncology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access